ANSI/PDA Standard on Cryopreservation of Cells for Cell and Gene Therapies Receives Complete Recognition Status by U.S. FDA CBER

The 2021 standard is included in a cohort of standards relevant to regenerative medicine therapies recognized either completely or partially by the Center for Biologics in 2023.

Regulatory Blue

This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.

On Mar. 25, 2024, PDA announced at its 2024 Annual Meeting in Long Beach, Calif., "ANSI/PDA 02-2021 Cryopreservation of Cells for Use in Cell Therapies, Gene Therapies, and Regenerative Medicine Manufacturing" has been included in a listing of recognized standards for regenerative medicine therapies by the U.S. FDA Center for Biologics Evaluation and Research. FDA released the list following the publication of "Guidance for Industry: Voluntary Consensus Standards Recognitions Program for Regenerative Medicine Therapies" in October 2023.

ANSI/PDA 02-2021 received the status of "Complete Recognition," a designation meaning the entire content of the standard is recognized. This is the first standard published by ANSI/PDA recognized by FDA since PDA became an ANSI-accredited standards developer in 2017.

"FDA's recognition of ANSI/PDA 02-2021 represents an important milestone for PDA and our standards-setting program," said Glenn Wright, PDA president & CEO. "We cannot thank the teams of experts enough that work diligently with PDA's staff to bring these standards to fruition, and recognition by FDA further demonstrates the scientific and technical value of their work."

The full title of ANSI/PDA Standard 02-2021 is: "Cryopreservation of Cells for Use in Cell Therapies, Gene Therapies, and Regenerative Medicine Manufacturing: An Introduction and Best Practices Approach on How to Prepare, Cryopreserve, and Recover Cells, Cell Lines, and Cell-Based Tissue Products." The standard provides guidance on how to establish suitable procedures for the cryopreservation and recovery of biological cells for use in cell and gene therapy products and regenerative medicine manufacturing either as an intermediate step or when cryopreservation is the final step. It presents cryopreservation as a modular process and describes key details that should be considered when developing a cryopreservation and recovery process for a specific use-case.

The standard is available at PDA's Bookstore.

PDA has submitted additional ANSI/PDA standards to FDA for consideration under the standards recognition program.

Fill out the form below to request more information about ANSI/PDA Standard on Cryopreservation of Cells for Cell and Gene Therapies Receives Complete Recognition Status by U.S. FDA CBER
List: Digitalization Companies From PACK EXPO
Looking for CPG-focused digital transformation solutions? Download our editor-curated list from PACK EXPO featuring top companies offering warehouse management, ERP, digital twin, and MES software with supply chain visibility and analytics capabilities—all tailored specifically for CPG operations.
Download Now
List: Digitalization Companies From PACK EXPO
FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
FDA warning letters surge - is your team prepared?